|Epigentek Launches Post-Bisulfite DNA Library Preparation Method Used In Whole Genome Bisulfite Sequencing
|NEW YORK, August 21 - Farmingdale-based epigenetics company Epigentek has launched a new product, the EpiNext Post-Bisulfite DNA Library Preparation Kit (http://www.epigentek.com/catalog/epinext-post-bisulfite-dna-library-preparation-kit-p-3615.html), for the use of constructing DNA libraries directly from bisulfite-treated DNA for whole genome bisulfite sequencing (WGBS).
Bisulfite conversion is an essential process of modifying DNA so that methylated cytosine bases can be detected via sequencing. DNA methylation is a widely studied mechanism of epigenetics and could help to elucidate our understanding of gene regulation involvement in serious diseases such as cancer.
Currently used whole genome bisulfite sequencing methods need rather large amounts of DNA (great than 1 µg) as input material, as well as requiring the need to first shear DNA and ligate adapters to DNA fragments prior to bisulfite conversion. This procedure causes a substantial amount of DNA fragments contained in adapter-DNA fragment constructs to become broken, forming mono-tagged templates that eventually become removed during library enrichment. Consequently, incomplete coverage and biases occur when performing whole genome bisulfite sequencing.
The innovative technology developed by Epigentek allows bisulfite-treated DNA to be directly used for ligation, thereby eliminating the possibility of breaking adapter-ligated fragments, which can often occur in currently used next generation bisulfite sequencing methods. The commercial kit, based on this technology, has high sensitivity and efficiency, enabling input DNA to be as low as 1 ng, and could be used for precious or limited biological samples such as tumor biopsy samples, early embryos, embryonic tissues, and circulating DNA.
About Epigentek Group Inc. Epigentek is a leading biotechnology company that focuses on developing and providing innovative technologies and products as a complete and systematic solution for epigenetic related research and drug discovery. Visit our informative website at www.epigentek.com.